Show simple item record

dc.contributor.authorDi Micco, Ren_US
dc.contributor.authorO'Connell, RLen_US
dc.contributor.authorBarry, PAen_US
dc.contributor.authorRoche, Nen_US
dc.contributor.authorMacNeill, FAen_US
dc.contributor.authorRusby, JEen_US
dc.date.accessioned2017-04-21T16:25:10Z
dc.date.issued2017-01en_US
dc.identifier.citationEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, 43 (1), pp. 68 - 75en_US
dc.identifier.issn0748-7983en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/610
dc.identifier.eissn1532-2157en_US
dc.identifier.doi10.1016/j.ejso.2016.08.013en_US
dc.description.abstract<h4>Introduction</h4>Bilateral mammoplasty (BM) can optimise oncological safety and aesthetic outcomes in women with large or ptotic breasts whose tumour to breast volume ratio or tumour location pose a challenge to standard breast-conserving therapy (BCT) and for whom mastectomy (with or without reconstruction) may be the only alternative.<h4>Methods</h4>We undertook a comprehensive analysis of surgical outcomes (complications according to the Clavien Dindo classification), acute radiation morbidity (Radiation Therapy Oncology Group classification), oncological outcomes, and patient satisfaction (BREAST-Q questionnaire) in women who underwent BM for breast cancer (BC) from June 2009-November 2014.<h4>Results</h4>168 women were included. Median age was 55 years (range:33-84) and median tumour size at imaging 35 mm (range:0-170). Median specimen weight was 242 g (range 39-1824). The wise pattern technique was used in 87.5% of procedures. At least one complication occurred in 68 (40.5%) women, mostly Clavien Dindo grade 1. Grade 3 complications were infrequent (8.9%) but occurred mainly on the therapeutic mammoplasty (TM) side (p < 0.05). Complications were associated with higher BMI, specimen weight and longer time to radiotherapy (p < 0.05). Median follow-up was 37 months (range: 13-77). Local recurrence occurred in 3 (1.8%), distant metastases in 5 (3.0%), and 10 (6.0%) women have died. The median score for 'satisfaction with breasts' was 77 (range: 0-100).<h4>Conclusions</h4>This study provides concurrent data on surgical, oncological and patient-reported outcomes. It offers evidence that BM is an effective treatment for breast cancer in large- or ptotic-breasted women.en_US
dc.formatPrint-Electronicen_US
dc.format.extent68 - 75en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectHumansen_US
dc.subjectBreast Neoplasmsen_US
dc.subjectPostoperative Complicationsen_US
dc.subjectTreatment Outcomeen_US
dc.subjectMammaplastyen_US
dc.subjectFollow-Up Studiesen_US
dc.subjectEstheticsen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectMiddle Ageden_US
dc.subjectPatient Satisfactionen_US
dc.subjectFemaleen_US
dc.subjectSurveys and Questionnairesen_US
dc.titleBilateral mammoplasty for cancer: Surgical, oncological and patient-reported outcomes.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-08-10en_US
rioxxterms.versionofrecord10.1016/j.ejso.2016.08.013en_US
rioxxterms.licenseref.startdate2017-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncologyen_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume43en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorRusby, Jenniferen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record